Latest Market Conditions News

Reliance Worldwide Corporation Limited reported a solid 14.8% increase in net sales for the first half of FY25, driven by the Holman acquisition and organic growth, yet signals a cautious outlook for the remainder of the year amid persistent macroeconomic headwinds.

Reliance Worldwide Corporation posts a robust 14.8% sales increase and a 31.8% jump in net profit for H1 FY25, driven by the Holman acquisition and solid cost efficiencies.

Turners Automotive Group has raised its FY25 profit guidance to at least NZ$53 million, marking its fifth consecutive record profit despite challenging economic conditions.

Morphic Ethical Equities Fund Limited reported a robust turnaround with a $2.96 million profit after tax for the half-year ended December 2024, reversing last year’s losses despite no dividends declared.

Citigroup Global Markets Australia has announced a 45-cent unfranked dividend for its CitiFirst Self-Funding Instalment MINIs, with key dates aligned to CPU ordinary shares. The dividend will reduce outstanding loan amounts for MINI holders, impacting their financial positions.

VanEck Investments Limited has released its indicative dividends calendar for 2025, outlining expected dividend timings for over 50 exchange-traded funds (ETFs). This comprehensive schedule offers investors clarity on dividend announcements, ex-dates, and payment dates across a diverse range of funds.

Simonds Group delivered a resilient $13.6 million EBITDA in 1H FY25 amid a soft residential market and announced a strategic acquisition of Dennis Family Homes to fuel future growth.

Simonds Group reported a resilient first half of FY25 with EBITDA growth despite market softness and announced a strategic acquisition to strengthen its market position.

HiTech Group Australia Limited has reported a robust half-year performance with a 29% increase in net profit and a strategic focus on high-margin ICT services amid growing market demand.

PYC Therapeutics has launched a A$145.8 million pro-rata accelerated non-renounceable entitlement offer to fund late-stage clinical trials across its pipeline targeting rare diseases with high unmet needs. The capital raise aims to extend the company’s cash runway beyond FY27, supporting four drug candidates through critical human safety and efficacy milestones.

Pivotal Metals’ recent FLTEM survey at Horden Lake reveals large undrilled conductors, signaling significant potential for resource expansion both near surface and at depth. The findings set the stage for a robust drilling campaign aimed at unlocking substantial copper-nickel-PGM mineralisation.

New Hope Group delivered a robust quarterly performance with a 21.8% rise in underlying EBITDA and a 33% jump in saleable coal production for the first half of FY25, underpinned by operational efficiencies and strategic investments.